Philip Morris International expands Zyn portfolio following FDA approval

The US Food and Drug Administration (FDA) has approved 11 additional Zyn nicotine pouch products for distribution in the United States. This regulatory decision expands the portfolio for Philip Morris International, specifically including higher-dose Zyn Ultra pouches with 9 milligrams of nicotine in flavors such as citrus, menthol, and wintergreen.

The FDA justified the authorization by noting lower levels of harmful ingredients compared to other oral and smokeless tobacco products. This follows a June 2026 decision where the agency classified 20 Zyn variants as less harmful than cigarettes. These approvals are expected to support Philip Morris International's strategic shift toward smoke-free products and may positively impact the company's revenue mix and profitability during the 2026 fiscal year.